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Calpain is activated in experimental uremia: Is calpain a media- Uremia has long been associated with a high incidence
tor of uremia-induced myocardial injury? of cardiovascular mortality [1], but little is known of the
Background. The cysteine proteases calpain and caspase-3 mechanism of how uremia causes myocardial injury. Theare known mediators of cell death. The aim of this study was
aim of this study was to determine whether the cytosolicto assess their contribution to the tissue damage found in exper-
imental uremia. cysteine proteases calpain and caspase-3 have a role in
Methods. Calpain and caspase-3 activities were measured in the development of uremia-induced tissue injury. Both
the hearts of rats that were sham-operated (control), sham- proteases have many common substrates and both cleaveoperated and spontaneously hypertensive (SHR), and those
cytoskeleton-associated proteins that have a role in therendered uremic by 5/6 nephrectomy (uremic). In an in vitro
study, heart myoblasts (Girardi) were incubated with human structural integrity of the cell membrane [2]. Calpains
serum from healthy subjects (control serum conditioned media, are present in all mammalian tissues and at least 14
CSCM) or uremic patients (uremic serum conditioned media, isoforms of calpain have been identified [3]. Calpain-1USCM), in the presence and absence of calpain and caspase-3
(-calpain) and calpain-2 (m-calpain) are the best char-inhibitors. After 48 hours the activity of calpain and caspase-3
was measured, and cell injury determined by DNA fragmenta- acterized isoforms and both are known to be present
tion (ELISA) and lactate dehydrogenase (LDH) release. An in cardiac tissue, with calpain-2 being predominant [4].
in situ assay was designed to study how USCM affects calpain Caspase-3 is considered to be a common downstreamactivity over time.
apoptosis effector, while calpain has been implicatedResults. In the in vivo study, mean calpain activities were
almost identical in the control and SHR groups, but calpain in both apoptotic and necrotic pathways [2]. Calpain is
and caspase-3 activities were much elevated in the uremic group known to be a mediator of rat hypoxic/ischemic and
(P  0.01 and 0.001 respectively vs. control). The SHR group ischemic/reperfusion injury in the myocardium [5, 6],had significantly higher mean arterial blood pressure (P 
and of multiple organ injury/dysfunction in hemorrhagic0.001 vs. control, 0.01 vs. uremic). In the in vitro study calpain
activity and DNA fragmentation were markedly higher in shock/reperfusion injury [7]. In addition, calpain has re-
USCM treated cells compared to CSCM (both P0.05). Both cently been implicated as an intermediary of acute renal
were reduced in USCM cells containing calpain inhibitors (E64d, cell death in a hypoxia/reoxygenation model [8]. Calciumcalpastatin, or PD 150606). LDH release was raised also in
is a prerequisite for calpain activation and is known toUSCM treated cultures (P  0.05), which only the E64d treat-
ment could significantly reduce (P 0.02). Caspase-3 activities be elevated subsequent to ischemia/reperfusion injury
were similar in USCM and CSCM groups. The in situ assay [9, 10]. Caspase-3 activity is also heightened in myocar-
showed significant increases in calpain activity in USCM dial ischemia [11], and non-selective caspase inhibitiontreated cells compared to CSCM after just 3.5 hours (P0.01).
has been shown to reduce myocardial infarct size in anConclusions. In vivo results suggest that the increases in cal-
pain and caspase-3 activity in uremic rat hearts were primarily ischemic/reperfusion rat model [12].
due to uremia and not to hypertension. In vitro data demon- We postulated that calpain and/or caspase-3 are acti-
strate that uremia-induced cell injury can be attenuated by cal- vated in the uremic heart and therefore might participatepain inhibition. Therefore, it is likely that calpain is a mediator
in the development of uremia-induced myocardial injury.of uremia-induced myocardial injury.
The role of calpain seems particularly relevant, as cal-
cium homeostasis is known to be altered in the uremicKey words: calpain, caspase-3, myocardial injury, hypertension, cardio-
vascular disease, tissue injury, apoptosis, left ventricular hypertrophy. myocardium [13]. Since hypertension is prevalent in ure-
mia, we assessed calpain and caspase-3 activities in threeReceived for publication July 29, 2002
groups of rats: sham-operated controls (controls), sham-and in revised form October 2, 2002
Accepted for publication October 21, 2002 operated spontaneously hypertensive rats (SHR), and
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(uremic). Calpain and caspase-3 activities were mea- Measurement of mean arterial pressure
sured in whole heart homogenates by activity assays that Femoral artery cannula insertion was performed 24
use synthetic fluorescent peptides as substrates. Further- hours prior to blood pressure recordings. Measurements
more, the activities of the proteases were studied using were made under quiet resting conditions with the rat
Western blots of the known substrate -fodrin by the free to move within the cage. To record blood pressure
identification of calpain/caspase-3 specific breakdown the catheter was clamped while the distal (knotted) end
products (BDPs). The 145 kD BDP is produced solely was cut off with scissors, then the catheter was connected
by calpain while the 150 kD fragment is formed both by to a pressure transducer (Model number 60-3003; Har-
calpain and caspase-3 activity [2]. Linear densitometry vard Apparatus, Boston, MA, USA) through a length
was performed on the 145/150 BDP doublet (as these of tubing, and the clamp released. An analogue-to-digital
individual BDPs could not easily be discriminated), converter (Dataq Instruments Inc., Akron, OH, USA)
which therefore provided evidence of the activity of both allowed the output from the pressure transducer to be
proteases. continuously displayed and recorded on a PC using Win-
An in vitro model of uremia was designed to determine daq (Dataq Instruments Inc.) digital chart recorder soft-
the role of calpain and caspase-3 in the development of ware. MAP was determined by placing a 1 mL air-filled
uremia-induced myocardial injury. In this model human- tube in parallel with the arterial line through a three-way
derived myoblasts were incubated with media enriched tap; arterial pressure traces were adequately damped to
with either human sera from healthy human volunteers give a virtually flat mean arterial signal. The arterial
or from patients with end-stage renal disease. To determine cannula was then used to acquire blood for analysis.
if any injurious effects to the myoblasts treated with uremic
serum were due to calpain or caspase-3 activation, the ef- Cell culture
fect of adding specific protease inhibitors was investigated. Human-derived Girardi cells were obtained from the
Three chemically distinct, cell-permeable calpain inhibitors European Collection of Animal Cell Cultures (ECACC,
were studied, PD 150606 (3-[4-iodophenyl]-2-mercapto- Porton Down, UK). Cells were cultured in EMEM media
[Z]-2-propenoic acid) and calpastatin peptide, which are
containing 2 mmol/L glutamine, 10% fetal calf serum
highly specific for calpain, and E64d ([2S,3S]-trans-epoxy-
(FCS), 1% non-essential amino acids (NEAA) from
succinyl-l-leucylamido-3-methylbutane ethyl ester) which
GIBCO (Life Technology Ltd, Paisley, UK) and anti-additionally inhibits other cysteine proteases. Caspase-3
biotic (100 U/mL penicillin, 100g/mL streptomycin andactivity was reduced with the cell permeable inhibitor
0.25 g/mL amphotericin B) in 25 cm3 tissue cultureDEVD-CHO.
flasks. Cultures were maintained in media containing
10% FCS while experiments were conducted in media
METHODS containing 5% FCS and 5% human serum from healthy
volunteers or patients with renal failure.Animals
All animal procedures were ethically approved and In vitro model of uremia
performed under current United Kingdom Home Office
Serum was obtained from patients with ethical ap-regulations (Project license number 70/5014). Male Wistar
proval and informed consent (ELCHA Research EthicsKyoto (WKY) rats and the genetically related SHR
Committee, P/97/334). All patients were treated by he-strain were obtained from Harlan UK Ltd. (Bicester,
modialysis, not on antihypertensive therapy, and samplesOxon, UK). One group of rats was made uremic by
were taken just prior to dialysis. Control samples were5/6 nephrectomy using an established two-stage surgical
from normotensive individuals and matched for genderprocedure (uremic) [14]. A second group of WKYs were
(all male), but not for age (in years  SE, controls sham-operated upon by removing the renal capsule and
38.8  2.3, uremic patients  50.1  6.2, mean time onreplacing the intact kidney (controls), while a third group
dialysis 2.8  0.6). However, the ages of the two groupsconsisted of sham-operated SHRs (N  7 for all three
were not statistically different (P 0.086, N 8). Serumgroups). SHR and control animals were pair-fed with the
samples from each individual was prepared in mediasub-nephrectomized animals to ensure that significant
(0.5 mL FCS, 0.5 mL human serum, 9 mL of EMEMdifferences in body weights did not occur. The study
media) and was divided into two flasks of subconfluentlasted for 12 weeks post-surgery. Rats were housed indi-
cells (cells confluent at 48 hours), one of which was usedvidually and given water ad libitum. Mean arterial blood
as a time 0 hour baseline.pressure (MAP) was determined on conscious unre-
Calpain inhibitors and the caspase-3 cell permeablestrained animals intra-arterially (see below). At the end
inhibitor DEVD-CHO (CN Biosciences UK Ltd, Not-of the study the animals were killed by cervical disloca-
tinghamshire, UK) were added to uremic serum condi-tion, and the hearts were promptly removed and kept
frozen at 80C. tioned media (USCM) at the start of the experiment.
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The concentration of inhibitors was determined from the 2-mercaptoethanol (pH 7.3). Calcium-free buffer was
prepared in assay buffer containing 20 mmol/L EGTAhighest effective concentration that did not produce cell
injury in the cells treated with normal serum conditioned and 25 mmol/L EDTA (pH 7.3). Calcium buffer con-
sisted of assay buffer with 2.5 mmol/L CaCl2 added (pHmedia (CSCM). This was because, although high concen-
trations of PD 150606 (100 mol/L) could completely 7.3). Freshly thawed hearts were weighed prior to the
addition of chilled calcium-free buffer (5 mL/g tissue).inhibit calpain activity in vitro, it also caused a marked
increase in lactate dehydrogenase (LDH) release (data Tissue was disrupted with a sintered glass homogenizer
prior to centrifugation (14,000  g, 4C, 30 min; Sorvalnot shown). After (0 and) 48 hours of incubation at 37C
in a humidified environment of air/CO2 (19:1), cells were RMC 14). The assay was then performed on this superna-
tant after it was diluted fivefold in calcium-free buffer.scraped off and centrifuged (100  g, room temperature
for 5 min). An aliquot of each CSCM and USCM used To four tubes containing 500 L of diluted supernatant,
one pair had 1.5 mL of calcium-free buffer added, and thewas reserved prior to the experiment, at times 0 and 48
hours, and then stored at20C for the LDH assay. Cell other pair had the same volume of calcium buffer added.
After a 10 minute pre-incubation period of shaking in apellets were resuspended in 400 L of cold assay buffer
(63.2 mmol/L imadazole-HCl containing 10 mmol/L of water bath at 37C, 10 L of the substrate N-succinyl-Leu-
Tyr-AMC (10 mmol/L in DMSO) was added to all tubes.2-mercaptoethanol, pH 7.3) containing 10mol/L digito-
nin, 1 mmol/L egtazic acid (EGTA), 0.1 mmol/L ethyl- After 30 minutes of incubation fluorescence was detected
at 380 nm excitation and 460 nm emission (Shimadzu RF-enediaminetetraacetic acid (EDTA; pH 7.3), and kept
on ice for 30 minutes with frequent mixing. Samples 5000; Shimadzu UK Branch, Milton Keynes, UK).
were then centrifuged (14,000  g, 4C, 30 min; Sorval
Calpain activity in cell lysatesRMC 14), the cell pellets discarded, with the lysates kept
on ice until assayed for calpain, before being frozen at The assay described in the last section was further
modified in order to determine calpain activity in cell20C.
lysates. Lysates were kept on ice during assay. Calcium-
Calpain activity assays free buffer was prepared in assay buffer containing 10
mmol/L EGTA and 1 mmol/L EDTA (pH 7.3). CalciumThe assays described in our study used synthetic pep-
tides as substrates that contain a molecule that fluoresces buffer consisted of assay buffer with 5.0 mmol/L CaCl2
added (pH 7.3). Sample lysate (10 L) was added to fouronly after protease cleavage. The peptides were not spe-
cific for calpain, so the assay conditions were manipu- wells of a black polypropylene microtiter assay plate,
followed by 90 L of calcium-free buffer to two of thelated to ensure that only the activity of calpain was mea-
sured. This involved the use of physiological conditions wells and 90 L of calcium buffer to the remaining pair
of wells. After 10 minutes of pre-incubation with shaking(where cathespins were known to be inactive), the mea-
surement of calcium dependent activity only (cathespins in an incubator at 37C, 2 L of the substrate N-succinyl-
Leu-Leu-Val-Tyr-AMC (1 mmol/L in DMSO) was addedand caspases were calcium-independent), or as in the
case of the in situ assay (calpain activity in situ) by the to all wells. Fluorescence was detected at 380 nm excita-
tion and 460 nm emission on a microtiter fluorescenceuse of calpain-specific inhibitors. The use of these pep-
tides for the measurement of calpain has recently been plate reader (BMG Fluorostar; BMG Labtechnologies
Ltd, Aylesbury, UK).reviewed [15]. With the exception of the in situ assay,
calpain activity was determined as the difference be-
Calpain activity in situtween the calcium dependent fluorescence and the non-
calcium dependent fluorescence. A 7-amino-4-methylcou- A 25 cm3 tissue culture flask of sub-confluent cells
were treated with 5 mL of 0.25% trypsin EDTA andmarin (AMC; ICN Biomedicals Ltd., Thame, Oxfordshire,
UK) standard curve was constructed for each assay with seeded into a 96 well tissue culture plate with 150 L of
EMEM containing 10% FCS media/well. After 24 hourseach calibrant containing the same concentration of
DMSO as the samples. Calpain activity was expressed the wells consisted of a monolayer of cells. The cell
culture media was then removed and replaced with 150as nmol of AMC released per minute of incubation time
per mg of total protein. L of human serum enriched media solutions (N  7 in
each group) containing 5% FCS supplemented with 5%
Calpain activity in rat hearts of either control (CSCM) or uremic serum (USCM).
Each media solution was added to 8 wells of the tissueCalpain activity was determined using an assay proce-
dure that was modified from those described by Sasaki culture plate containing Girardi cell monolayers and a
blank plate (without cells). To both plates 50 mol/L ofet al for measurement in purified porcine kidney [16] and
by Edelstein et al in rat proximal tubules [17]. Briefly, the the calpain-specific inhibitor calpeptin (in DMSO) was
added to four wells, while the remaining 4 wells wereassay was performed as follows: Assay buffer consisted
of 63.2 mmol/L imadazole-HCl containing 10 mmol/L of treated with the same quantity of DMSO (2 L, 1.33%).
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After 10 minutes of pre-incubation at 37C, 2 L of the Quantification of cell death by LDH assay
substrate N-succinyl-Leu-Leu-Val-Tyr-AMC (1 mmol/L Lactate dehydrogenase activity was measured in the
in DMSO) was added to all wells containing media in incubation media prior to (background control) and at
both plates. Fluorescence was detected at 380 nm excita- the end of the experiment (48 h) using a colorimetric
tion and 460 nm emission on a microtiter fluorescence assay (Cytotoxicity Detection Kit; Roche Diagnostics).
plate reader. Calpain activity was determined for each Cytotoxicity (%) was calculated by the subtraction of
media solution as the difference between the mean fluo- the background control from the 48 hour sample and
rescence in the samples without the calpain inhibitor and expressed as a percentage of a positive control (2% Tri-
those with the inhibitor. The calpain activity of each ton X-100), minus background control, corrected for to-
media solution alone (from the blank plate) was then tal lysate protein.
subtracted from the calpain activity from the tissue cul-
Other measurementsture plate to ensure that only the calpain activity in the
cells was measured. In addition to the human serum Total protein concentration was determined by Brad-
media samples, 8 wells of each plate were treated with ford assay and serum creatinine by the Jaffe´ rate method
media supplemented with 10% FCS (negative control), (Beckman 2 Analyzer; Beckman Coulter U.K. Ltd., High
Wycombe, UK). Serum calcium and phosphate concen-and a further 8 wells with 10% FCS containing 2 mol/L
trations were performed by VETLAB services (South-of the calcium ionophore A23187 (positive control).
water, Sussex, UK).These samples were then treated with calpeptin (or
DMSO) and substrate as described earlier.
Western blotting
Caspase-3 activity in tissue homogenates Tissue homogenates were diluted tenfold in calcium-
free buffer and lysates were used neat. All samples wereThe tissue homogenates were prepared as before (Cal-
initially diluted in running buffer (2 L buffer/8 L ofpain activity in rat hearts) and caspase-3 activity was
sample), before being boiled at 99C for five minutes.determined by a commercially available activity assay
Samples were placed on ice before gel loading (10 g(Promega, Southampton, Hampshire, UK). The assay
protein/well of homogenates and lysates, 20 ng of humanwas performed as stated in the kit documentation using
erythrocytes calpain-1 and rat recombinant calpain-2;20 L of homogenate per tube in the standard assay
CN Biosciences UK Ltd, Nottinghamshire, UK). Pro-format. Fluorescence was detected at 380 nm excitation
teins were separated on a 7.5% poly-acrylamide gel (Na-and 460 nm emission on a spectrofluorophotometer (Shi-
tional Diagnostics Ltd, Hessle, UK) and electro-blottedmadzu). Caspase-3 activity was expressed as nmol of
onto a polyvinylidine (PVDF) membrane (Immobion-AMC released per minute of incubation time per mg of
P, Sigma, UK) and blocked overnight at 4C with 5%total protein.
BSA. Membranes were then probed with mouse anti
-fodrin monoclonal antibody diluted 1:1000 (AffinitiCaspase-3 activity in cell lysates
Research Products Ltd., Mamhead, UK) or goat anti-As described in the last section, except that 10 L of
calpain-1 or -2 (1:1000; Santa Cruz Biotech, Autogencell lysate were used, the assay protocol was then as stated
Bioclear, Calne, UK). The secondary antibody was HRP
in the kit documentation for the 96-well plate format.
labeled IgG (1:2000; Santa Cruz Biotech). Comparative
Fluorescence determined on a microtiter fluorescence densitometry was performed on the fodrin 145/150 kD
plate reader. doublet and the calpain-2 band visualized using chemilu-
minescence (ECL; Autogen Bioclear).Quantification of cell death by DNA
Two of the membranes (Fig. 2 A, C) were strippedfragmentation assay
by incubation in 62.5 mmol/L Tris (pH 6.8), 2% SDS,
Cell death was detected by a DNA fragmentation en- 100 mmol/L 2-mercaptoethanol for 30 minutes at 50C.
zyme-linked immunosorbent assay (ELISA), which quan- After washing and re-blocking, the membranes were re-
tifies the mono- and oligonucleosomes in the cytoplasmic probed with a different primary antibody (Fig. 2 B, D).
fraction of cell lysates or incubation media (Cell Death
MaterialsDetection ELISAPLUS; Roche Diagnostics, Lewes, UK).
Lysates were diluted 20-fold in kit lysate buffer while Unless otherwise stated in the text, all chemicals were
cell incubation media were sampled neat. The assay was obtained from the Sigma-Aldrich Chemical Company
performed as described in the kit insert with DNA frag- (Poole, Dorset, UK).
mentation expressed as an enrichment factor (absorbance
Statistical evaluationvalue for 48-hour experimental sample/absorbance value
of 0 hour sample) from a time 0 hours baseline sample All data are presented as means  SE of N observa-
tions, where N represents the number of animals or se-per mg of total lysate protein.
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rum-enriched media samples studied. Data were initially it failed to reach statistical significance (Fig. 3A; N 
tested for normal distribution (Shapiro-Wilk test) by us- 7). Therefore, the density of the calpain-2 band did not
ing Analyse-it software for Microsoft Excel (v1.62; always reflect total calpain activity, as all of the uremic
Leeds, UK). Animal data were analyzed by one-way hearts had much higher calpain activities than their
ANOVA (matched) with Tukey’s post-hoc test, and cell paired control and SHR hearts (Fig. 1D).
culture data by the unpaired Student t test. When com-
In vitro model of uremiaparing the means of two groups, P 0.05 was considered
significant. The mean creatinine concentration in the serum used
in these cell culture experiments was 77 mol/L (5.3,
SE) for the healthy volunteers, while in the patients withRESULTS
renal failure it was 883 mol/L (67 SE, N  8, P The 5/6 nephrectomized rats had (as expected) mark-
1  108).edly elevated serum creatinine concentrations compared
Cell death (as determined by DNA fragmentation andto both the control and SHR groups, thereby confirming
LDH release) and calpain activity were significantlythe onset of uremia (Fig. 1A).
higher in the lysates and supernatants (incubation me-The hearts of the uremic rats were significantly larger
dia) from cells treated with USCM for 48 hours com-(as determined by wet weight) than those from the con-
pared with those treated with CSCM (Fig. 4 A–D). Thetrol group (Fig. 1B) while the SHR group mean heart
elevation in lysate DNA fragmentation and calpain activ-size was not statistically greater than controls, indicating
ity in USCM cells were significantly reduced in USCMthe development of uremia-induced left ventricular hy-
cells containing PD 150606, E64d (Fig. 4 A, D), and calpa-pertrophy (LVH) in the subtotally nephrectomized ani-
statin peptide (Fig. 4 E, F). Calpastatin-negative controlmals.
peptide (scramble peptide of identical amino acids) asThe uremic and SHR groups both had significant
higher mean arterial blood pressures (MAPs) but MAP predicted had no detectable effect (Fig. 4 E, F) on lysate
was highest in the SHR group (Fig. 1C). This suggests DNA fragmentation and calpain activity. However, cal-
that the SHR group can act as a control for the hyperten- pain inhibition was unable to lower LDH release in the
sion associated with uremia and that the effects found USCM cells using PD 150606 (Fig. 4C) or calpastatin
in this study are due predominantly to uremia and not peptide (data not shown), but E64d, a broader-based
to high blood pressure. cysteine protease inhibitor, did reduce LDH release (Fig.
The hemoglobin concentrations revealed that the ure- 4C). Western blots confirmed the ability of PD 150606
mic animals were anemic (in g/dL  SE, control 14.9  at 1 mol/L to lower calpain activity in this model by
0.8, SHR 15.8  1.3, uremic 8.6  1.0, control vs. uremic reducing the formation of calpain/caspase-3 specific fo-
P  0.01, SHR vs. uremic P  0.005, control vs. SHR  drin BDPs (Fig. 2E). Caspase-3 activity was found to be
NS). There were no significant differences in the final body no higher in lysates from USCM treated cells and those
weights of the rats (in gSE, control 3692.3, SHR 366 incubated with CSCM (Fig. 5A), while a specific caspase-
8.8, uremic 314  19.5). There were also no significant 3 inhibitor had no discernable effect on the degree of
differences in serum calcium (in mmol/L  SE, control DNA fragmentation (Fig. 5B), despite greatly reducing
1.74  0.28, SHR 1.88  0.10, uremic 1.49  0.31) and caspase-3 activity (Fig. 5C).
serum phosphate concentrations (in mmol/L  SE, con-
trol 3.94  1.63, SHR 2.32  0.18, uremic 4.88  1.69). In situ calpain assay
Calpain and caspase-3 activities were found to be
The in situ calpain assay revealed that calpain activityhigher in the homogenized hearts from the uremic group
in cultured myoblasts rises sharply within hours of treat-compared to sham-operated animals (Fig. 1 D, and E).
ment with USCM. Figure 6A shows mean calpain activi-This was confirmed by the increase in fodrin BDP 145/
ties in Girardi cells after a six hour incubation in media150 kD doublet intensity in the uremic group compared
enriched with CSCM or USCM (N  7), while Figureto control animals (Figs. 2D and 3B). It is noticeable
6B shows the rise in calpain activity over time (N that the relative increase in calpain activity with respect
3). The addition of the calcium ionophore A23187 (1to the control group was much greater than for caspase-3
mol/L) caused a rapid rise in calpain activity (Fig. 6B).(3.4-fold rise for calpain compared to a 2.0-fold for cas-
A23187 is known to fluoresce, but as we detected thepase-3). Calpain-2 immunoreactivity was clearly visible
difference in activity in A23187 treated cells with andon Western blots (Figs. 2C and 3A) and markedly more
without calpeptin, this fact is not relevant in this system.calpain-2 immunoreactivity than calpain-1 was evident
FCS (10%) treatment promoted calpain activity in ain control animal hearts (Fig. 2 A, B). The density of
similar manner to control media (5% FCS and 5% serumthe calpain-2 band tended to be greater in the uremic
animal group compared to control and SHR groups, but from normal subjects).
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Fig. 1. Serum creatinine (A ), final heart wet weight (B ), conscious mean arterial blood pressure (C; MAP), homogenate calpain (D ) and caspase-3
(E ) activities in animals 12 weeks after the uremic animal group were 5/6th nephrectomized (N  7 sets of 3 animals).
DISCUSSION LVH appears to be induced by uremia rather than high
blood pressure, as the more hypertensive SHR animalsOur study illustrates the injurious effect upon cardiac
had heart weights not significantly greater than controltissue of experimental uremia and that uremia causes
rats (Fig. 1 B, C). The elevation of total calpain activitysignificant increases in calpain activity. This is supported
and caspase-3 activity in the uremic rats is unequivocalby the finding that the mean heart weight for the uremic
(Fig. 1 D, E) and is supported by the increase in thegroup of animals was significantly higher than the control
density of the fodrin 145/150 kD BDP (Figs. 2D andgroup (Fig. 1B), indicating the development of left ven-
tricular hypertrophy (LVH) in this group of animals. 3B). However, the density of the calpain-2 immunoreac-
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Fig. 2. Western blots demonstrating that control rat hearts (C heart) contain mostly calpain-2 immunoreactivity with very little calpain-1 evident
(A, B). (A) Cells were stripped and re-probed with anti-calpain-2 antibody (B). Purified calpain-1 was derived from porcine erythrocytes and
purified calpain-2 is rat recombinant. Both positive controls (20 ng) are indicated by dark bands when probed by the appropriate primary antibody,
but only calpain-2 immunoreactivity is clearly visible in the heart homogenate. Calpain-2 activity was always much higher in uremic heart tissue,
but this was not always evident from Western blots (C ). (D ) An increase in fodrin 145/150 breakdown products (BDPs) in uremic hearts is shown.
(E ) One mol/L (arrowed) of the specific calpain inhibitor PD 150606 is able to inhibit the formation of 145/150 fodrin BDPs in uremic serum
conditioned myoblasts. Panels (C) and (D) portray 3 “triplets” of hearts that were representative of the 7 “triplets” studied. Panel (E) is rep-
resentative of two separate experiments that were both run on two gels.
tive band did not always correspond with the increase in increase of other calpain isoforms. A further possibility is
that the calpain present in the uremic heart is more activetotal calpain activity in the uremic heart (Figs. 2C, 3A, and
1D). This could possibly be due to uremia causing a de- than that in a healthy heart. Certainly the evidence of the
in situ data showing that calpain activity was significantlycrease in endogenous calpastatin (calpain inhibitor) or an
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interest to examine whether serum from patients treated
with continuous ambulatory peritoneal dialysis could in-
duce calpain activation in the same manner. The mean
age of the uremic patient group was higher than the
control group (although not statistically), but it is doubt-
ful that age is a factor in this study, as the two eldest
uremic patients (aged 65 and 79) induced the lowest
increases in calpain activity of the uremic population
studied (data not shown).
The reduction of lysate DNA fragmentation in uremic
serum-treated cells incubated with two distinct and spe-
cific calpain inhibitors suggests that calpain has an impor-
tant role in the development of uremia-induced myocar-
dial injury. In addition E64d (which inhibits calpain and
other cysteine proteases) was able to reduce both DNA
fragmentation and LDH release, thereby indicating a
role for additional proteases in uremia induced cell death.
The elevation of DNA fragmentation found in cell ly-
sates (Fig. 4A), and incubation media (Fig. 4B) suggests
that uremia induced injury involves both apoptotic and
necrotic cell death. Thus, it is possible that specific cal-
pain inhibition can decrease uremia induced apoptosis
but not necrosis. This indicates that the cells are destined
to die by events upstream of calpain. This is in part
analogous to the findings of Suzuki et al, who found that
the inhibition of caspases in peroxide-induced apoptosis
caused a decrease in apoptosis but increased the rate of
necrosis [18]. There are many examples of calpain having
Fig. 3. Densitometry data derived from Western blots for calpain-2 a significant role in apoptosis and necrosis. In PC12 cul-
bands and the fodrin 145/150 BDP doublet (N  7). No statistical tures, calpain has been shown to possess the more domi-
differences were found in the densities of the calpain-2 band (A ). The
nant role in hypoxic cell death than the caspases [19],fodrin 145/150 kDa doublet band density was significantly increased in
the uremic hearts (B ). and oxidative stress induced apoptosis can be restricted
by calpain inhibition [20]. The pro-apoptotic BH3-only
Bcl-2 family member protein Bid was found to be cleaved
during myocardial ischemia/reperfusion to an active frag-
higher in cells incubated with USCM compared to those ment by calpain causing cytochrome c release without
incubated with CSCM after just 3.5 hours (Fig. 6B) sug- caspase activation [21]. Specific calpain inhibition also
gests that calpain activation in uremia is not due solely has been shown to protect against virus-induced apo-
to increases in calpain expression. Calpain activity was ptotic myocardial injury in neonatal mice [22].
still elevated in situ after six hours (Fig. 6A) and in the The influence of caspase-3 in this study was harder to
in vitro model after 48 hours (Fig. 4D). However, when determine. Although the mean caspase-3 activity was
interpreting the results of this in vivo study it is important significantly higher in the hearts of uremic animals com-
to acknowledge the limitations of this work. Firstly, the pared to control rats, the fold rise was modest when
uremic animals also were found to be anemic, and sec- compared to the increase in calpain activity. Further-
ondly, the SHR group of animals failed to develop sig- more, mean caspase-3 activities in lysates derived from
nificant LVH. Therefore, it is not possible to state that cells incubated in USCM were no higher than those in
the changes in the cysteine protease activities in the cells incubated in CSCM (Fig. 5A). This might be be-
uremic rat myocardium are purely as a result of uremia. cause uremia is inducing cell death solely via a necrotic
This is because LVH itself and/or anemia might also play pathway, but the presence of DNA fragmentation in cell
a role. lysates indicates the presence of some apoptotic death.
The sera used in these cell culture experiments were This can be likened to the findings of Ueda et al, who
obtained from healthy human volunteers and uremic studied the effects of hypoxia/reoxygenation injury (which
patients treated by hemodialysis. It is feasible that hemo- is classically described as a form of necrotic cell death)
dialysis itself rather than uremia might contribute to the in kidney proximal tubules [23, 24]. They found evidence
of DNA fragmentation and endonuclease activation butactivation of calpain in vitro. Therefore, it would be of
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sult is between these two extremes, and complete repair
cannot be accomplished that an apoptotic cascade of
events can occur. There also have been numerous reports
of apoptosis that are caspase-3 independent [25–30]. An
example of this is that cadmium induced apoptosis in
U937 cells appears to occur through two independent
pathways, a Ca2	/calpain dependent pathway and a cas-
pase-mitochondria dependent pathway [26]. In addition
Huang and Wang have suggested that ischemia and trau-
matic brain injuries that result in oncosis and apoptosis
are mediated via calpain activation independently of cas-
pases [3]. Therefore, it is possible that uremia is inducing
necrotic and/or apoptotic cell death that is independent
(at least in vitro) from caspase-3. It also is feasible that
caspase-3 does play a role in uremia-induced cell injury
in cell culture, but we did not detect it due to measuring
its activity at an inappropriate time point. However, this
seems unlikely, as the use of a potent cell permeable
caspase-3 inhibitor was unable to reduce uremia-induced
DNA fragmentation in this study (Fig. 5B) despite reduc-
ing caspase-3 activity greatly (Fig. 5C). Recent work by
Knaapen et al suggests that cardiomyocytes in heart fail-
ure suffer from caspase-independent autophagic cell death
rather than apoptotic cell death [31]. However, the role
of caspase-3 and other caspases still warrants further study
because they are known to interact with calpain in a
number of diverse pathways [32–34]. Of particular rele-
vance might be the finding that caspase-3 and procas-
pase-3 are substrates for calpain with calpain cleavage
rendering caspase-3 (and other caspases) inactive [33, 35].
It might be that an elevation in caspase-3 activity in
uremic serum-treated cells is being prevented by a rise
in caspase-3 deactivation due to the increase in calpain
activity.
The reason why calpain is activated in uremia as yet
can only be speculated upon. It is possible that calcium
has a role as calcium homeostasis is altered in both exper-
imental and clinical uremia [13–14]. In this study no
evidence of an increase in circulating Ca2	 concentra-Fig. 5. Caspase-3 activity (A ) in lysates from Girardi cells incubated
for 48 hours in healthy and uremic serum-conditioned media. The cell tions in the uremic rat was found. Future work will inves-
permeable caspase-3 inhibitor DEVD-CHO did not reduce the degree tigate the simultaneous detection of calpain and Ca2	in DNA fragmentation induced by uremia (B ) despite significantly
in situ in order to resolve the mechanism for calpainreducing caspase-3 activity (C, N  6 to 8).
activation in experimental uremia. We will focus also on
the precise contribution of calpain and other cysteine
proteases prior to and during the development of uremia,no morphological evidence of apoptosis. Their work con-
and the use of multiple cysteine protease inhibitors bothcludes that when the degree of ischemia is severe the cells
exhibit a necrotic form of death, and where it is mild in isolation and combination to prevent uremia-induced
myocardial injury. A limitation of this cell culture studythe cells can undergo complete repair. It is when the in-

Fig. 4. DNA fragmentation in (A ) lysates and (B ) incubation media, lactate dehydrogenase (LDH) cytotoxicity in incubation media (C ), and
calpain activity in lysates (D ) derived from Girardi cells incubated for 48 hours in healthy and uremic serum-conditioned media, with and without
the calpain inhibitor PD 150606 or E64d, a cysteine protease inhibitor. DNA fragmentation and calpain activity (E and F ) in uremic-serum
conditioned media with and without calpastatin peptide and a negative control scramble peptide (N  6 to 8 for all experiments).
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Fig. 6. In situ calpain activity in monolayers
of Girardi cells incubated with media enriched
with serum from healthy human volunteers
(controls) or patients with end-stage renal fail-
ure (N  7) for 6 hours (A ). (B ) Uremic
serum-enriched media elicits a significantly
higher calpain activity than control media
after just 3.5 hours (210 min, P  0.01, 250
min P  0.02, 300 min P  0.02, and 350 min
P 0.02; N 3). Calpain activity rose sharply
when treated with the calcium ionophore
A23187.
is that it has employed cultured myoblasts rather than assay revealed that significant increases in calpain activ-
primary cells because of the obvious advantages in work- ity occur within 3.5 hours in living heart derived my-
ing with immortalized cells. However, from the findings oblasts incubated in media enriched with uremic serum
of this study, which show that calpain rises rapidly when compared to those incubated with serum from healthy
treated with USCM, it would appear practical in the human volunteers. We conclude that calpain is probably
future to examine the effect of USCM treatment further a key mediator in the development uremic cardiomyopa-
by using freshly isolated rat myocytes. thy, but that other cysteine proteases are likely to play
To summarize, we have demonstrated that calpain an important role.
activity is elevated in both in vivo and in vitro models
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